Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
The Journal of Allergy and Clinical Immunology
|
September 22, 2014
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions
Anna Sala-Cunill, Jenny Björkqvist, Riccardo Senter, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
June 27, 2025
Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study
Massimo Triggiani, Jessica Hobart, Iván Alvarez-Twose, et al.
European Journal of Dermatology : EJD
|
December 5, 2022
Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
Gemma Melé-Ninot, Esther Serra-Baldrich, Jorge Spertino, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
March 5, 2026
Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks
Timothy Craig, Emel Aygören-Pürsün, Jonathan A Bernstein, et al.
The New England Journal of Medicine
|
July 26, 2018
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
Emel Aygören-Pürsün, Anette Bygum, Vesna Grivcheva-Panovska, et al.
The Journal of Allergy and Clinical Immunology. Global
|
April 25, 2025
Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor
Markus Magerl, Marc A Riedl, Luisa Karla Arruda, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 31, 2025
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
Henriette Farkas, John Anderson, Laurence Bouillet, et al.
The Lancet. Haematology
|
March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Marcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The New England Journal of Medicine
|
March 23, 2017
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Hilary Longhurst, Marco Cicardi, Timothy Craig, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 12, 2024
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
Remy S Petersen, Lauré M Fijen, Christian Apfelbacher, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
The Journal of Allergy and Clinical Immunology
|
September 22, 2014
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions
Anna Sala-Cunill, Jenny Björkqvist, Riccardo Senter, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
June 27, 2025
Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study
Massimo Triggiani, Jessica Hobart, Iván Alvarez-Twose, et al.
European Journal of Dermatology : EJD
|
December 5, 2022
Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
Gemma Melé-Ninot, Esther Serra-Baldrich, Jorge Spertino, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
March 5, 2026
Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks
Timothy Craig, Emel Aygören-Pürsün, Jonathan A Bernstein, et al.
The New England Journal of Medicine
|
July 26, 2018
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
Emel Aygören-Pürsün, Anette Bygum, Vesna Grivcheva-Panovska, et al.
The Journal of Allergy and Clinical Immunology. Global
|
April 25, 2025
Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor
Markus Magerl, Marc A Riedl, Luisa Karla Arruda, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 31, 2025
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
Henriette Farkas, John Anderson, Laurence Bouillet, et al.
The Lancet. Haematology
|
March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Marcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The New England Journal of Medicine
|
March 23, 2017
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Hilary Longhurst, Marco Cicardi, Timothy Craig, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 12, 2024
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
Remy S Petersen, Lauré M Fijen, Christian Apfelbacher, et al.
Page
of 8